clinical trial · NCT07029581
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Lewy Body Dementia PsychosisACP-204Placebo
brief summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
started
Aug 6, 2025
primary completion
Feb 1, 2028
completion
Mar 1, 2028
last updated
Apr 22, 2026
official title
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol